All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2010-019464-37 | effects of dynamic co2 therapy in periodic breathing in heart failure patients Effetti della somministrazione dinamica di anidride carbonica nella sindrome delle apnee centrali in pazienti con scom... | not-yet-due | |
Ongoing | 2010-024485-21 | Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY Infusione di dipiridamolo contro adenosina nella val... | not-yet-due | |
Ongoing | 2013-000759-41 | A prospective, open-label, single center, cross-over, controlled, randomized, phase III study to test superiority of the oral solution of synthetic thyroxine compared to tablet preparation for treat... | not-yet-due | |
Completed, but no date, and reported results | 2015-005383-42 | Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients). Ph... | bad-data | |
Completed, but no date, and reported results | 2015-005384-16 | A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyloid... | bad-data | |
Completed, but no date, and reported results | 2017-001660-38 | A prospective triple-arm, monocentric, phase-II explorative study on evaluation of diagnostic efficacy of the PET tracer (18F)-florbetaben (Neuraceq®) in patients with cardiac amyloidosis - FLORAMICAR... | bad-data | |
Reported results | 2018-000832-82 | GLYcemic Control with EMpagliflozin vs standard of care in patients with type 2 dIAbetes and Heart failure: effects on cardiac remodeling and neurohormonal activation EFFETTI DI EMPAGLIFLOZIN SU RI... | 2022-04-07 | due-trials |
Other | 2021-000730-34 | HeAd-to-head compaRison of single versus dual antiplatelet treatMent strategY after percutaneous left atrial appenDAge closure: A MULticenter, randomizEd sTudy the ARMYDA-AMULET study Confronto tr... | not-yet-due | |
Completed, but no date Terminated | 2021-001564-26 | Evaluation of the cardioprotective metabolic effect of trimetazidine in patients with myocardial ischaemia Valutazione dell’effetto metabolico cardioprotettivo della Trimetazidina in pazienti con i... | bad-data | |
Ongoing | 2022-000686-40 | Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis Studio prospettic... | not-yet-due | |
Ongoing | 2022-002585-33 | A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) Studio multicentrico di fase 3 sulla diagnosi non invasiva di amiloidosi cardiaca da catene... | not-yet-due |